Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL
Phase 3
Withdrawn
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Drug: PlaceboDrug: MAT9001 (omega-3 pentaenoic acid)
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Matinas Biopharma, Inc
- Registration Number
- NCT04662528
A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules
Phase 1
Completed
- Conditions
- Hypertriglyceridemia
- Interventions
- Drug: Drug Omega 3Drug: Drug Omega-3 Comparator
- First Posted Date
- 2014-12-05
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Matinas Biopharma, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT02310022
- Locations
- 🇨🇦
Pharma Medica Reserach Inc, Toronto, Ontario, Canada
© Copyright 2025. All Rights Reserved by MedPath